Coya Therapeutics, Inc. Update: A Planned Leadership Transition

This summary breaks down the latest news from Coya Therapeutics into plain English so you can understand the situation without needing a finance degree.

1. What happened?

Coya Therapeutics is completing a planned leadership change. Dr. Howard Berman, the company’s founder and Executive Chairman, stepped down on April 2, 2026. Mark H. Pavao has joined the Board of Directors to fill his seat. Mr. Pavao brings over 30 years of experience, including a senior role at Amgen, where he helped launch several major drugs.

2. Why does this matter?

While a founder leaving can sometimes worry investors, this is a planned, orderly transition—not a sudden exit caused by scandal or disagreement.

The board is effectively trading a founder’s scientific vision for a commercial expert’s experience. This signals that the company is shifting its focus from "discovery" to "commercial readiness." They are now prioritizing the regulatory and logistical steps needed to get treatments approved and into the hands of patients.

3. What this means for the company’s future

Coya is moving from research to the commercial phase. By hiring Mr. Pavao, the company is prioritizing his specific expertise in FDA approvals and global drug distribution. This move is a strategic play to support the development and potential launch of their lead drug, COYA 302, which is currently being tested for ALS.

4. Who is affected?

• Investors: This signals that the company is maturing. Mr. Pavao’s experience is vital for managing the transition from Phase 2 trials to potential Phase 3 studies.
• Patients: This change happens at the board level and does not affect ongoing clinical trials. However, it strengthens the company’s ability to handle the manufacturing and distribution needed once a drug is approved.
• The Company: The company loses the founder’s daily guidance but gains a specialist in scaling operations. This is crucial for the ALSTARS trial, where the company must prove both that the drug works and that it can be produced at scale.

5. What happens next?

All eyes are on the clinical data. Coya is currently running the ALSTARS Phase 2 trial for COYA 302. Investors are waiting for these results, which will be the primary driver for the stock. After the data release, the company will likely discuss Phase 3 trial designs with the FDA, where Mr. Pavao’s experience will be a key asset.

6. The bottom line for your portfolio

This is a healthy evolution as the company grows, and you should not expect major operational disruptions. To stay informed, monitor the next earnings call to see how the new board influences the company’s spending and development timeline.

A final note of caution: The main risk remains the success of COYA 302. No matter how much experience a board member has, the company’s value is ultimately tied to the clinical success of its lead drug. If the Phase 2 data is poor, board expertise cannot save the drug.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial, investment, or legal advice. Always do your own research before making any trading decisions.